Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib for GVHD Prevention Post-HSCT
NCT03082677Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in graft-versus-host disease (GVHD), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2017; status: completed.
02
Drugs
ixazomib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03082677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082677.